IL101600A - Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them - Google Patents

Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them

Info

Publication number
IL101600A
IL101600A IL10160092A IL10160092A IL101600A IL 101600 A IL101600 A IL 101600A IL 10160092 A IL10160092 A IL 10160092A IL 10160092 A IL10160092 A IL 10160092A IL 101600 A IL101600 A IL 101600A
Authority
IL
Israel
Prior art keywords
synthetic
antisense oligodeoxynucleotides
pct
gene
pharmaceutical compositions
Prior art date
Application number
IL10160092A
Other languages
English (en)
Other versions
IL101600A0 (en
Inventor
Hermona Soreq
Haim Zakut
Fritz Eckstein
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL10160092A priority Critical patent/IL101600A/xx
Publication of IL101600A0 publication Critical patent/IL101600A0/xx
Priority to DE69308833T priority patent/DE69308833T2/de
Priority to US08/318,826 priority patent/US5891725A/en
Priority to PCT/EP1993/000911 priority patent/WO1993021202A1/fr
Priority to AU40399/93A priority patent/AU665087B2/en
Priority to EP93911467A priority patent/EP0636137B1/fr
Priority to CA002118235A priority patent/CA2118235C/fr
Priority to AT93911467T priority patent/ATE150029T1/de
Priority to JP5517984A priority patent/JPH08504083A/ja
Priority to US08/850,347 priority patent/US6110742A/en
Publication of IL101600A publication Critical patent/IL101600A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
IL10160092A 1992-04-15 1992-04-15 Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them IL101600A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL10160092A IL101600A (en) 1992-04-15 1992-04-15 Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
JP5517984A JPH08504083A (ja) 1992-04-15 1993-04-15 合成アンチセンスオリゴデオキシヌクレオチドとそれらを含む医薬組成物
AU40399/93A AU665087B2 (en) 1992-04-15 1993-04-15 Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US08/318,826 US5891725A (en) 1992-04-15 1993-04-15 Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
PCT/EP1993/000911 WO1993021202A1 (fr) 1992-04-15 1993-04-15 Oligodesoxynucleotides anti-douleurs synthetiques et compositions pharmaceutiques les contenant
DE69308833T DE69308833T2 (de) 1992-04-15 1993-04-15 Synthetische "antisense" oligonucleoside und diese enthaltende arzneimittel
EP93911467A EP0636137B1 (fr) 1992-04-15 1993-04-15 Oligodesoxynucleotides anti-douleurs synthetiques et compositions pharmaceutiques les contenant
CA002118235A CA2118235C (fr) 1992-04-15 1993-04-15 Oligonucleotides antisens de synthese et compositions pharmaceutiques en renfermant
AT93911467T ATE150029T1 (de) 1992-04-15 1993-04-15 Synthetische ''antisense'' oligonucleoside und diese enthaltende arzneimittel
US08/850,347 US6110742A (en) 1992-04-15 1997-05-02 Synthetic antisense oligodeoxynucleotides targeted to AChE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10160092A IL101600A (en) 1992-04-15 1992-04-15 Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL101600A0 IL101600A0 (en) 1992-12-30
IL101600A true IL101600A (en) 2000-02-29

Family

ID=11063549

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10160092A IL101600A (en) 1992-04-15 1992-04-15 Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them

Country Status (9)

Country Link
US (1) US5891725A (fr)
EP (1) EP0636137B1 (fr)
JP (1) JPH08504083A (fr)
AT (1) ATE150029T1 (fr)
AU (1) AU665087B2 (fr)
CA (1) CA2118235C (fr)
DE (1) DE69308833T2 (fr)
IL (1) IL101600A (fr)
WO (1) WO1993021202A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2110946A1 (fr) 1992-12-09 1994-06-10 Elazar Rabbani Methode pour rendre un element du corps immunocompatible au moyen d'un construit d'acide nucleique, construit d'acide nucleique servant a inhiber ou a reguler la fonction d'un gene de la reponse immunitaire et element immunocompatible contenant un construit d'acide nucleique servant a inhiber ou a reguler la fonction d'un gene de la reponse
GB9519299D0 (en) 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
US8551970B2 (en) 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
CA2274985C (fr) * 1996-12-12 2010-08-24 Hermona Soreq Oligodesoxynucleotides anti-sens synthetiques cibles pour l'acetylcholinesterase humaine
CA2283068A1 (fr) * 1997-03-06 1998-09-11 Yissum Research Development Company Of The Hebrew University In Jerusale M Procedes et compositions permettant la traitement d'une lesion du systeme nerveux central
JP2003511393A (ja) * 1999-10-07 2003-03-25 エイブイアイ バイオファーマ， インコーポレイテッド アンチセンス組成物および癌処置法
US6869795B1 (en) 1999-10-07 2005-03-22 Avi Biopharma, Inc. Antisense compositions and cancer-treatment methods
IL132972A0 (en) * 1999-11-16 2001-03-19 Yissum Res Dev Co Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
AU2001250856A1 (en) * 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7049121B2 (en) * 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
WO2003054182A2 (fr) * 2001-12-21 2003-07-03 Nexia Biotechnologies, Inc. Production de butyrylcholinesterases par des mammiferes transgeniques
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
IL158600A (en) * 2003-10-26 2015-07-30 Hermona Soreq Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
WO2007087113A2 (fr) * 2005-12-28 2007-08-02 The Scripps Research Institute Utilisation de transcrits d'arn antisens et non codants naturels comme cibles de médicaments
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
MY188457A (en) * 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
US9289475B2 (en) 2008-11-06 2016-03-22 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
US20110293608A1 (en) 2008-12-03 2011-12-01 The Johns Hopkins Univeristy Annexin a2 as immunological target
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
EP2370581B1 (fr) 2008-12-04 2016-08-03 CuRNA, Inc. Traitement de maladies apparentées au facteur de croissance de l'endothélium vasculaire (vegf) par inhibition du transcript antisens naturel du vegf
CN102317458B (zh) * 2008-12-04 2018-01-02 库尔纳公司 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
WO2010107733A2 (fr) 2009-03-16 2010-09-23 Curna, Inc. Traitement de maladies associées au facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2
JP5904935B2 (ja) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
CA2761152A1 (fr) 2009-05-06 2010-11-11 Opko Curna, Llc Traitement de maladies associees aux genes du metabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gene du metabolisme et du transport des lipides
KR101742334B1 (ko) 2009-05-08 2017-06-01 큐알엔에이, 인크. Ｄｍｄ 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
EP2435571B1 (fr) 2009-05-28 2016-12-14 CuRNA, Inc. Traitement de maladies associées à un gène antiviral grâce à l'inhibition d'un produit de transcription antisens naturel d'un gène antiviral
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
CA2765889A1 (fr) 2009-06-24 2010-12-29 Opko Curna, Llc Traitement de maladies associees au recepteur de facteur necrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2
EP2446037B1 (fr) 2009-06-26 2016-04-20 CuRNA, Inc. Traitement de maladies associées aux gènes liés au syndrome de down par inhibition des gènes liés au syndrome de down médiée par le produit de transcription antisens naturel
CN102712925B (zh) 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
CN102762731B (zh) 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2464731B1 (fr) 2009-08-11 2016-10-05 CuRNA, Inc. Traitement de maladies associées à l'adiponectine (adipoq) par inhibition du produit de transcription anti-sens naturel d'une adiponectine (adipoq)
CA2771228C (fr) 2009-08-21 2020-12-29 Opko Curna, Llc Traitement des maladies liees a « l'extremite c de la proteine chip (proteine interagissant avec hsp70) » par inhibition du transcrit antisens naturel de chip
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
EP2480669B1 (fr) 2009-09-25 2017-11-08 CuRNA, Inc. Traitement de maladies associées à la filaggrine (flg) par modulation de l'expression et de l'activité de flg
CN102712927B (zh) 2009-12-16 2017-12-01 库尔纳公司 通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
EP2516664B1 (fr) 2009-12-21 2015-07-22 Pharmathene Inc. Butyrylcholinestérases recombinantes et produits de troncature de ceux-ci
CN102781480B (zh) 2009-12-23 2018-07-27 库尔纳公司 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
CN102770540B (zh) 2009-12-29 2017-06-23 库尔纳公司 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
EP2519633B1 (fr) 2009-12-29 2017-10-25 CuRNA, Inc. Traitement de maladies liées au facteur respiratoire nucléaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1
JP6083735B2 (ja) 2009-12-31 2017-02-22 カッパーアールエヌエー，インコーポレイテッド インスリン受容体基質２（ｉｒｓ２）および転写因子３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるインスリン受容体基質２（ｉｒｓ２）関連疾患の治療
CN102906264B (zh) 2010-01-04 2017-08-04 库尔纳公司 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
JP6027893B2 (ja) 2010-01-11 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
NO2529015T3 (fr) 2010-01-25 2018-04-14
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
EP2553098B1 (fr) 2010-04-02 2017-10-11 CuRNA, Inc. Traitement de maladies liées au facteur de stimulation des colonies 3 (csf3) par inhibition du produit de la transcription antisens naturel en csf3
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
CA2798218A1 (fr) 2010-05-03 2011-11-10 Curna, Inc. Traitement de maladies liees a une sirtuine (sirt) par inhibition de la transcription antisens naturelle pour donner une sirtuine (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
NO2576783T3 (fr) 2010-05-26 2018-04-28
US8980858B2 (en) 2010-05-26 2015-03-17 Curna, Inc. Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
WO2011163499A2 (fr) 2010-06-23 2011-12-29 Opko Curna, Llc Traitement de maladies liées à la sous-unité alpha du canal sodique voltage-dépendant (scna) par inhibition du produit de transcription naturel antisens à la scna
ES2663598T3 (es) 2010-07-14 2018-04-16 Curna, Inc. Tratamiento de enfermedades relacionadas con el homólogo de discos grandes (dlg) mediante la inhibición del transcrito antisentido natural a dlg
KR101886457B1 (ko) 2010-10-06 2018-08-07 큐알엔에이, 인크. 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
EP2630241B1 (fr) 2010-10-22 2018-10-17 CuRNA, Inc. Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua
WO2012068340A2 (fr) 2010-11-18 2012-05-24 Opko Curna Llc Compositions d'antagonat et leurs méthodes d'utilisation
KR102010598B1 (ko) 2010-11-23 2019-08-13 큐알엔에이, 인크. Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
WO2013036403A1 (fr) 2011-09-06 2013-03-14 Curna, Inc. Traitement de maladies liées à des sous-unités alpha de canaux sodiques voltage-dépendants (scnxa) avec de petites molécules
EP2898072A1 (fr) 2012-09-24 2015-07-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Restauration de la fonction cftr par modulation de l'épissage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1992003139A1 (fr) * 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Modulation par des oligonucleotides de l'adherence cellulaire

Also Published As

Publication number Publication date
DE69308833D1 (de) 1997-04-17
DE69308833T2 (de) 1997-06-19
US5891725A (en) 1999-04-06
WO1993021202A1 (fr) 1993-10-28
ATE150029T1 (de) 1997-03-15
AU4039993A (en) 1993-11-18
AU665087B2 (en) 1995-12-14
CA2118235A1 (fr) 1993-10-28
JPH08504083A (ja) 1996-05-07
CA2118235C (fr) 2008-07-15
IL101600A0 (en) 1992-12-30
EP0636137A1 (fr) 1995-02-01
EP0636137B1 (fr) 1997-03-12

Similar Documents

Publication Publication Date Title
IL101600A (en) Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
CA2229811A1 (fr) Oligonucleotides chimeres et hybrides inverses
CA2046916A1 (fr) Methodes de traitement du cancer au moyen d'oligonucleotides, et compositions
EP0939621A4 (fr) Inhibition de l'expression de la proteine bcl-2 par des nucleotides olidodesoxy antisens se presentant sous forme de liposomes
AU7621600A (en) Human rnase h and oligonucleotide compositions thereof
AU7572096A (en) Chimeric oligomers having an rna-cleavage activity
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
ZA935915B (en) Modified fungal cells and method for producing recombinant products
CA2205075C (fr) Reactif et methode d'inhibition de l'expression de n-ras
AU4339997A (en) Method for using oligonucleotides having modified cpg dinucleosides
WO1994025588A2 (fr) OLIGONUCLEOTIDES ANTISENS DESTINES AU TRAITEMENT DES EFFETS IMMUNO-SUPPRESSEURS DU FACTEUR TRANSFORMANT DE CROISSANCE-β (TGF-β)
GR3031218T3 (en) Medium for long-term proliferation and development of cells
CA2398432A1 (fr) Modulation de la reponse immunitaire stimulee par des oligonucleotides contenant du cpg a l'aide d'un changement de position de nucleosides
AU5959396A (en) Antisense oligonucleotide modulation of raf gene expression
Baserga Controlling IGF-receptor function: a possible strategy for tumor therapy
CA2259123A1 (fr) Oligonucleotides provenant des regions non traduites de genes constitutifs, et procede d'utilisation de ces oligonucleotides afin de moduler la croissance cellulaire
HU9403343D0 (en) New pharmaceutical uses of krill enzymes
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
EP0772621A2 (fr) Oligonucleotide a activite anti-gene mdr-1
Birek et al. Secretion of a bone resorbing factor by epithelial cells cultured from porcine rests of Malassez
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
AU5005093A (en) Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
EP0695354A1 (fr) OLIGONUCLEOTIDES ANTISENS DESTINES AU TRAITEMENT DES EFFETS IMMUNO-SUPPRESSEURS DU FACTEUR TRANSFORMANT DE CROISSANCE-$g(b) (TGF-$g(b))
IL146565A0 (en) A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
AU784358B2 (en) Antisense compositions and cancer-treatment methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired